Research Topics
| Brian K IronsSummaryAffiliation: Texas Tech University Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitorsBrian K Irons
Ambulatory Care Texas Tech University Health Sciences Center, School of Pharmacy, 3601 4th St Lubbock, TX 79430, USA
Curr Diabetes Rev 8:169-82. 2012..For patients with mildly elevated glucose concentrations, they are therapeutic options in both drug-naive patients as well as those not optimally controlled on other diabetes medications...
Quality of care of a pharmacist-managed diabetes service compared to usual care in an indigent clinicBrian K Irons
School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX 79430 8162, USA
Diabetes Technol Ther 10:220-6. 2008..This study evaluates the quality of care of a pharmacist-managed diabetes clinic focused on an indigent population and compares that quality of care to usual care in the same health care setting...- Valsartan-induced angioedemaBrian K Irons
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy Lubbock Programs, Lubbock, TX, USA
Ann Pharmacother 37:1024-7. 2003..To report a case of dose-dependent angioedema secondary to the use of the angiotensin-receptor blocker (ARB) valsartan... - Delaying the onset of type 2 diabetes mellitus in patients with prediabetesBrian K Irons
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX 79430 8162, USA
Pharmacotherapy 24:362-71. 2004..Pharmacists can promote awareness, counsel patients on intervention strategies to delay the onset of diabetes mellitus, and screen high-risk patients... - The use of angiotensin receptor blockers in the treatment of chronic heart failureBrian K Irons
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 8162, USA
J Cardiovasc Pharmacol 44:718-24. 2004..In patients with heart failure but preserved systolic dysfunction, candesartan showed no effects on mortality and only modest effects on morbidity... - Lipid management with statins in type 2 diabetes mellitusBrian K Irons
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX 79430 8162, USA
Ann Pharmacother 39:1714-9. 2005..To provide an update on lipid management and recent modifications in cholesterol guidelines for use of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), specifically in patients with diabetes... - Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitusBrian K Irons
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79430 8162, USA
Pharmacotherapy 26:168-81. 2006..Alterations in these risk factors are likely due to their effects on improving insulin sensitivity and/or glycemic control. Trials to assess whether thiazolidinediones actually reduce cardiovascular outcomes are continuing... - Evaluation of diabetes primary care and effects on health care charges in elderly patients with diabetiesBrian K Irons
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 8162, USA
Am J Med Sci 335:426-30. 2008..This study assessed diabetes out-patient care at a single institution in Medicare patients with significant health care expenditures and correlated the control of these patients with hospital admission rates and charges... - Planning and implementing an interdisciplinary diabetes workshop for healthcare professionalsGloria M Valdez
Nursing Faculty, Covenant School of Nursing, Lubbock, Texas, USA
J Contin Educ Nurs 38:232-7. 2007..The lessons learned during this project are provided for consideration by others seeking to address common concerns and challenges in other areas of clinical practice... - Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical CentersTimothy A Mazzolini
Department of Veterans Affairs, Lubbock VA Outpatient Clinic, Lubbock, TX 79412, USA
J Manag Care Pharm 11:763-71. 2005.... - Factors associated with increased hospital utilization in patients with heart failure and preserved ejection fractionRachel S Crowder
University Medical Center, Texas Tech University Health Sciences Center, Lubbock, Texas 79430 8162, USA
Pharmacotherapy 30:646-53. 2010..To determine whether controlling systolic blood pressure (SBP), pulse pressure, and heart rate in the outpatient setting is associated with decreased hospital utilization in patients with heart failure and preserved ejection fraction (PEF)... - Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metforminKrystal L Edwards
School of Pharmacy, Texas Tech University Health Sciences Center, Department of Pharmacy Practice, Veterans Administration North Texas Health Care System, Dallas, TX 75216, USA
Pharmacotherapy 28:506-21. 2008..Therefore, a standard of care cannot be provided; rather, clinicians must evaluate each patient to ascertain that patient's optimum therapy. In doing so, clinicians need to be familiar with the efficacy, safety, and cost of each agent... - Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individualsKathleen A Snella
School of Pharmacy, University of Missouri Kansas City, Columbia, MO 65211, USA
J Am Pharm Assoc (2003) 46:370-7. 2006..To assess a model to screen minority, elderly, and at-risk individuals for diabetes, hypertension, and dyslipidemia in pharmacy and non-health care settings... - The need for a community diabetes education curriculum for healthcare professionalsBrian K Irons
School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA
J Contin Educ Nurs 38:227-31. 2007..Fifty-five of those participants stated a strong interest in pursuing certified diabetes educator certification, which may significantly increase the number of certified diabetes educators in both rural and urban areas of West Texas... - A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinicBrian K Irons
Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, USA
Pharmacotherapy 22:1294-300. 2002..11 +/- 0.46, p = 0.003). Pharmacist-managed diabetes care was effective in improving glycemic control and was not associated with an increased risk for hypoglycemic events or unscheduled diabetes-related clinic visits... - Removing barriers to insulin useMolly G Minze
School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, USA
J Fam Pract 60:577-80. 2011..Patients with type 2 diabetes and their physicians are often reluctant to begin insulin therapy--despite evidence of its efficacy. Here's help in overcoming this other form of "insulin resistance.".. - An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonistsKrystal L Edwards
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA
Diabetes Technol Ther 14:951-67. 2012..For T2DM patients willing to use an injectable agent, exenatide and liraglutide offer another therapeutic option to control hyperglycemia with the potential for weight loss and may be combined with other agents safely... - Update on the management of dyslipidemiaBrian K Irons
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
Am J Health Syst Pharm 59:1615-25. 2002..The updated guidelines recommend more intensive lipid-lowering treatments for primary prevention in patients with two or more risk factors...